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ABSTRACT 
Data on neurobiological mechanisms underlying mood disorders are elusive; the 
aetiology of such states is multifactorial, including genetic predisposition and 
environmental factors. Diagnosis  is currently being made only on an interview-based 
methodology. Biological markers, which could improve the current classification, and 
in perspective, stratify patients on a biological basis into more homogeneous clinically 
distinct subgroups, are highly needed. We describe here a comparative proteomic 
analysis of peripheral lymphocytes from patients affected by acute psychotic bipolar 
disorder (PBD) (n = 15), major depressive episode (MDE) with no personal or family 
history of psychosis (n = 11), and a group of demographically matched healthy controls 
(HC) (n = 15). All patients were evaluated by means of Structured Clinical Interview for 
DSM-IV-Patient version (SCID-I-P), Positive and Negative Symptoms Scale (PANSS), 
Young Mania Rating Scale (YMRS), Hamilton Anxiety Rating Scale (HAM-A) and 
Hamilton Depression Rating Scale(HAM-D-17) questionnaires. Blood lymphocytes 
were obtained by gradient separation, and 2-DE was carried out on protein extracts. 
Significant differences in protein patterns among the three groups were observed. 
Thirty-six protein spots were found to be differentially expressed in patients compared 
to controls, which collapsed into 25 different proteins after mass spectrometry 
identification. Twenty-one of these proteins failed to discriminate between PBD and 
MDE, suggesting common signatures for these disorders. Nevertheless, after the 
western blot validation only two of the remaining proteins, namely LIM and SH3 
domain protein1, and short-chain specific acyl-CoA dehydrogenase mitochondrial 
protein, resulted in being significantly up regulated in PBD samples suggesting 
additional mechanisms that could be associated with the psychotic features of bipolar 
disorder. 
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INTRODUCTION 
 
Bipolar Disorder 
Bipolar disorder (BD) and severe clinical depression are a group of mental diseases, 
which often manifest themselves with dramatic changes in mood, energy, cognition, and 
behavior that fluctuate over time. Psychotic states characterized by auditory or visual 
hallucinations, and paranoid or delusional beliefs can also be present in the acute phase. 
The aetiology of these disorders is multifactorial including a complex interaction 
between genetic predisposition, with many genes each accounting for a small effect, and 
environmental factors, such as developmental abnormalities, trauma, substance abuse 
and social factors. Despite the abundance of research, data on neurobiological 
mechanisms underlying mood disorders are elusive, and diagnoses rely on clinical 
assessment of these dynamic symptoms mainly through interview-based methodology. 
Currently most used classification systems are the Diagnostic and Statistical Manual of 
Mental Disorders 4th Edition and the International Statistical Classification of Diseases 
(DSM-IV-TR) and Related Health Problems 10th Revision (ICD-10)[3]that are not 
evidence-based and many diagnostic criteria overlap with many other diseases with 
different aetiologies, such as neurological or organic conditions. There is no clear 
consensus on how many types of bipolar disorder exist[1] in the DSM-IV-TR and ICD-
10, bipolar disorder is conceptualized as a spectrum of disorders occurring on a 
continuum. The discrimination between the various clinical subtypes of bipolar 
spectrum is essentially based on the time course and the symptom of emotional 
connotation intercurrent. The DSM-IV-TR lists three specific subtypes[2]: 
Bipolar disorder I be characterized by the presence of at least a Mixed Episode, or by 
the presence of at least one major depressive episode, interspersed by at least one manic 
episode spontaneous. In most cases, or mixed manic episodes alternated with one or 
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more depressive episodes, though these are not required for diagnosis. In fact, In 2-10% 
of cases occur exclusively manic relapses, the latter forms that show more often a late-
onset. 
Bipolar disorder II on the other hand, shows a clinical course is characterized by at 
least one major depressive Episode (see dedicated paragraph), supplemented by at least 
one Hypomanic Episode spontaneous. 
Ciclotimico is a  disorder characterized by the development of numerous hypomanic 
episodes, alternating with periods characterized by the presence of depressive 
symptoms, which however are not sufficient to diagnose major depression. Not 
surprisingly, the course of the disorder remains unpredictable, and treatment options are 
unspecific leaving the practice mostly to the clinician’s personal experience. In order to 
be clinically useful, a diagnosis should be able to predict the prognosis, the course of 
illness and eventually the guide treatment choice, and such aims are better achieved 
when the classification of illnesses moves closer to underlying biological mechanisms. 
The identification of biological markers could improve the diagnosis and classification 
of mood disorder subtypes, as well as stratify patients into more homogeneous, 
clinically useful subpopulations. Biomarker studies on psychiatric disorders present 
peculiar hurdles such as the inherent difficulties in accessing relevant biological 
materials, since the main alterations appear to be in the brain. Almost all large-scale 
proteome studies in psychiatry have aimed to profile protein expression differences 
compared to control samples in a hypothesis-free manner. Proteomic profiling for 
psychiatric disorders has been initially carried out in brain tissue. Samples from major 
depression (MD), schizophrenia, BD and control subjects have been simultaneously 
analyzed[4]-[6]. 
Biomarkers in Psychiatry 
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According to the official definition by the National Institutes of Health (NIH), ‘‘a 
biomarker is a characteristic that is objectively measured and evaluated as an indicator 
of normal biological processes, pathogenic processes, or pharmacological responses to 
a therapeutic intervention’’[7]. The utilization of biomarkers for brain disorders is not a 
recent concept. In the nineteenth century, Kraepelin established a writing scale to 
stratify patients suffering from psychiatric disorders by measuring their writing pressure 
curves [8]. Due to the phenotypic heterogeneity and the lack of quantitative measures 
for disease symptoms, biomarker discovery in the field of neuroscience has been 
confronted with considerable challenges. This holds true especially for neuropsychiatric 
disorders where, despite tremendous progress in understanding brain function, the exact 
molecular underpinnings of mental dysfunction remain elusive. Because biomarkers can 
differentiate between distinct biological states, their availability is critical in clinical 
settings for premorbid diagnosis, patient stratification, and monitoring of disease 
progression and treatment. The use of biological markers in other areas of medicine has 
come a long way with advances in the fields of pathology, biochemistry and most 
notably genetics. For example, prevalent and debilitating diseases such as heart failure 
can be diagnosed with high sensitivity and specificity by measurement of levels of B-
natriuretic peptide (BNP). Certain types of cancer can be screened and monitored by 
specific tumor markers. The search for biological markers for psychiatric diseases has 
been going on for decades; however, previous experimental attempts have selected 
candidate biomarkers based on current models of disease pathogenesis. Due to the 
presumed high level of etiologic heterogeneity and the overlap of dimensions across 
mood disorders, there aren’t specific markers. Recent technological advances made it 
possible to leave the hypothesis-based approaches of biomarker discovery in favor of 
non-hypothesis-driven profiling experiments. Biomarkers may be in the form of genes, 
proteins and other molecules, or morphological characteristics, in any case they should 
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relate closely to the neurobiology representing the molecular correlate of the disorder, 
not merely the symptom or disease consequences. Diagnostic biomarkers, depending on 
the information they can provide, be used as prediction tools(e.g. subclinical markers, 
risk or vulnerability markers), this is of high importance in psychiatry as there is 
evidence that delays in diagnosis and intervention lead to poorer prognosis. Biomarkers 
could also be identified as diseases signatures (e.g. disease markers, stage or 
progression markers)[9], adding information on prognosis and course of illness. 
Moreover, in order to be translated into clinical practice biomarkers should also be 
measurable and reproducible over time, non invasive, easily available, cost-effective 
and provide with high sensitivity and specificity for the disease[10][11]. 
 
Proteomics in psychiatric disorders 
The first proteomics publication in psychiatric disease dates back to 2000 
[12].Biomarker studies on psychiatric disorders present peculiar hurdles such as the 
inherent difficulties in accessing relevant biological materials, since the main 
manifestations appear to be in the brain. Almost all large-scale proteome studies in 
psychiatry have aimed to profile protein expression differences compared to control 
samples in a hypothesis-free manner. Proteomic profiling for psychiatric disorders has 
been initially carried out in brain tissue. Studies in brain tissues, however, carry some 
limitations and the reasons are both methodological and theoretical. Indeed, brain 
samples need to be analyzed carefully to avoid post-mortem artefacts, they are a very 
valuable source for the generation of hypotheses with regard to the aetiology of a 
disorder; however, they can only give molecular information from the time of death. 
One additional limitation of post-mortem research is that results cannot be exported into 
animal models. Sampling peripheral tissues is important for diagnostic purposes as well 
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as for investigating treatment effect, therefore proteome of blood or cerebrospinal fluid 
is necessary to integrate findings between brain and periphery. 
 
 
Biological samples studies 
 
 Post mortem tissue. 
 
In schizophrenia brain tissue, deregulation of pathways associated with reactive oxygen 
species has been observed [13]as well as alterations in mitochondrial oxidative 
phosphorylation and glucose metabolism. Proteome analyses have identified differential 
expression of proteins involved in those processes, such as key enzymes associated with 
glucose metabolism including aldolase C (ALDOC), gamma enolase (ENO2), aconitase 
(ACO2), hexokinase (HK1), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a 
number of subunits of mitochondrial ATPase and proteins associated to oxidative stress 
[14]. Oligodendrocytes are responsible for myelination of axons in the central nervous 
system. Reduction or malformation of the myelin sheath can result in leakage and 
reduced propagation of nerve impulses. In addition, proteome analyses have confirmed 
this through identification of differentially expressed proteins such as Myelin basic 
protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and 20,30-cyclic 
nucleotide,30-phosphodiesterase (CNP)[14].Proteome analyses of human brain tissue of 
patients with bipolar disorder have also been performed. Dihydropyrimidinase-related 
protein-2 (DPYSL2) and glial fibrillary acid protein (GFAP) were found to be 
decreased in the frontal cortex (FC-BA10) suggestive of effects on brain development. 
The differential expression of several tubulin subunits suggested that cytoskeletal 
dysfunction may be an important component of bipolar disorder through an analysis of 
the anterior cingulate cortex (ACC-BA24)[16]. One common finding in proteomic 
studies of distinct brain regions from bipolar disorder patients is suggestive of a 
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dysfunction in energy metabolism[12][16], more prominently in the dorsolateral 
prefrontal cortex (DLPFC-BA9) where half of the identified differentially expressed 
proteins were involved in these pathways .At present, only two brain regions, the frontal 
cortex (FC) and accumbens (ACC), from depressed patients have been subjected to 
proteomic analyses, revealing differentially expressed proteins[12][16]. Altered 
expression of DPYSL2 was common to both studies, although this was down regulated 
in FC and up regulated in ACC. DPYSL2 plays a role in nervous system development 
and cell differentiation by regulating axonal guidance, neuronal growth cone collapse 
and cell migration, suggestive of alterations in brain development in depressed patients. 
The differential expression of carbonic anhydrase (CA2) and ALDOC was also 
common to both studies, implicating effects on energy metabolism. Both of these 
studies used brain tissue samples from the Stanley Neuropathology Consortium and 
analyzed samples from major depression, schizophrenia, bipolar disorder and control 
subjects simultaneously. 
 
 
 Serum 
Serum can be obtained in relatively large quantities, it can be sampled with minimal 
discomfort to the patient and therefore remains one of the most suitable methods to 
investigate diagnostic biomarkers and findings can be easily exported and used to 
develop large scale tests .While there is yet no clear biomarker, there is increasing 
evidence to suggest that disease related changes can be detected outside the brain. 
Multiple contributing factors including growth factors and/or pro-inflammatory 
cytokines are deregulated in psychotic disorders. And also multiple endocrine (Thyroid, 
sex steroids, HPA axis) and metabolic (insulin resistance) function appear altered in 
mood disorders. Serum levels of the inflammatory markers sTNFR1 and sTNFR2, were 
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found to be higher in chronic institutionalized patients with schizophrenia than in 
controls, however no correlation with symptom severity was found[17]. Dietrich-
Muszalska and Olas[18]showed that collagen-stimulated platelet aggregation was 
significantly lower in the schizophrenic patients group compared to healthy controls .In 
another study the activity of the platelet antioxidative enzyme superoxide dismutase 
(SOD), and the levels of thiobarbituric acid reactive species (TBARS) were measured as 
oxidative stress indicators. Results suggested an enhanced generation of reactive oxygen 
species and significantly lower SOD activity in schizophrenia patients compared to 
healthy controls[19].
.
A recent review of 185 publications described a total of 273 
schizophrenia biomarkers identified in serum and/or plasma. The findings suggested an 
ongoing immunological and inflammatory process in schizophrenia, accompanied by 
altered cortisol levels which suggested activated stress response and altered 
hypothalamic-pituitary-adrenal axis function in these patients [20]. 
 
 
 Lymphocytes 
Metabolism and regulatory processes of viable tissue of subjects from with central 
nervous system (CNS) disorders are difficult to assess. Sampling peripheral tissues (i.e. 
blood and cerebrospinal fluid)[21] is important for diagnostic purposes as well as for 
investigating treatment effects. 
Abnormalities of the anterior cingulate cortex have previously been described in 
schizophrenia, major depressive disorder and bipolar disorder .In fact, there is now an 
increasing body of evidence pointing to a close integration between the central nervous 
system (CNS) and immunological functions with lymphocytes playing a central role. 
Numerous studies showed similarities between receptor expression and mechanisms of 
transduction processes of cells both in the nervous system (e.g. neurons and glia) and in 
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lymphocytes [21].In several neuropsychiatric disorders, the alteration of metabolism 
and cellular functions in the CNS, as well as disturbances in the main neurotransmitter 
and hormonal systems, are concomitant with altered function and metabolism of blood 
lymphocytes. Taken together the authors suggest further detailed exploration of the 
expression of genes and gene products in lymphocytes that could be used as markers for 
a variety of psychiatric disorders and could predict responses to psychotropic drugs. 
Furthermore, these parameters may help to identify responsible genes that underlie 
process of the disease. The lymphocyte may therefore serve as an easily accessible 
model to investigate alterations in immune– neuroendocrine interactions observed in 
psychiatric disorders. The authors therefore suggest that they be used as a neuronal and 
genetic probe in experimental and clinical research in psychiatry[22]. Recently, 
proteomic analysis has been performed on lymphocytes of schizophrenic[23]and bipolar 
patients [24][25] suggesting the presence of potential biomarkers such as alpha 
defensins and phosphoglyceratemutase 1 (PGAM1) respectively. 
 
 
Proteomics 
In the last few years, it has become widely recognized that the genome only represents 
the first layer of complexity. Biological function is carried by the dynamic population of 
proteins, moreover, only the characterization of the proteins themselves can reveal 
posttranslational modifications (e.g., phosphorylation, sulfation, glycosylation, 
ubiquitination, and methylation) and give insight into protein-protein interactions and 
subcellular localization, thus providing clues about function. For these reasons, there is 
increasing interest in the field of proteomics: the large-scale identification of proteins 
contained in cells, tissues or body fluids[26]. The proteome was originally defined as 
the complete protein complement expressed by a genome[26]. However, this definition 
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does not take into account that the proteome is a highly dynamic entity that will change 
based on cellular state and the extracellular milieu. Therefore, the definition of a 
proteome should specify that it is the protein complement of a given cell at a specified 
time, including the set of all protein isoforms and protein modifications [27]. Proteomic 
analyses can be used to identify the protein content in complex biological samples such 
as biological fluids and tissue extracts, and to determine the quantitative or qualitative 
differences for each polypeptide contained in different samples. It is expected that the 
proteomic profiling patterns resulting from such analyses define comprehensive 
molecular signatures in health and disease. The exploitation of a proteomic approach for 
the study of different diseases has led to the hypothesis that multiple biomarkers or a 
panel of biomarkers shown by proteomic profiling may correlate more reliably with a 
specific disease than a single biomarker or protein. Expression pattern of a known 
biomarker or correlation of expression of several known biomarkers can be a valuable 
research and clinical tool for monitoring disease or treatment progression [28]. 
 
Two-dimensional electrophoresis. 
 
The identification of proteins from complex biological sample has traditionally been 
performed using 2-D PAGE coupled with mass spectrometry (MS). Two-dimensional 
electrophoresis (2-DE) separates proteins by both their isoelectric point (pI) and 
molecular weight. With this technique proteins are resolved into discrete spots, each of 
which represents a single protein that can be selectively excised and identified by MS. 
The high resolution of 2-DE allows the researcher to pick only the proteins of interest 
while bypassing the more abundant or less interesting proteins [29]. 
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Sample preparation. 
 
Preparation of samples for 2-D PAGE involves solubilization, denaturation and 
reduction to completely break up the interactions between the proteins [30]. Although 
desirable, there is no single method of sample preparation that can be universally 
applied due to the diverse samples which are analyzed by 2-DE gel electrophoresis [31]. 
The ideal sample solubilization procedure for 2-D PAGE would result in the disruption 
of all non-covalently bound protein complexes and aggregates into a solution of 
individual polypeptides [32]. However, whatever method of sample preparation is 
chosen, it is most important to minimize protein modifications which might result in 
arte-factual spots on the 2-DE maps [31]. Samples containing urea must not be heated 
as this may introduce considerable charge heterogeneity due to carbamylation of the 
proteins by isocyanate formed from the decomposition of urea. Generally speaking, 
samples should be subjected to as minimum handling as possible and kept cold at all 
times [33]. Protein extracts should not be too diluted to avoid loss of protein due to 
adsorption to the wall of the vessel (glass or plastic). If samples are rather diluted and 
contain relatively high concentrations of salts which can interfere with IEF, samples 
may be desalted [31]. Alternatively, proteins can be precipitated with ice-cold TCA / 
acetone to remove salts. Diluted samples with a low salt concentration may also be 
applied directly without further treatment, if the dried IPG strips are reswollen in 
sample solution. In this case, solid urea, CHAPS and dithiothreitol (DTT) are added to 
the sample until the desired concentration is obtained [31][34]. 
 
First dimension. 
 
Iso-electro focusing (IEF) represents the first dimension of 2-DE and it is performed in 
individual immobilized pH gradients (IPG) strips. Each sample protein applied to an 
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IPG strip will migrate to its isoelectric point (pI), the point at which its net charge is 
zero. There are strips with broad or narrow pH gradient (e. g., 3-10; 4-7; 4-9; 6-10; 5-6; 
9-12; 10-12). Dried gel strips containing immobilized pH gradient were commercially 
introduced in 1991 (Pharmacia Biotech, Immobiline® DryStrip Gel), their adoption for 
the first dimension of 2-DE has produced significant improvement over the classical O’ 
Farrell carrier ampholyte-based 2-DE separation [35]. In the original 2-DE the required 
pH gradient is established by the migration of individual species of carrier ampholytes 
to their respective pI. Variations of the complex carrier ampholyte mixtures result in 
variations in the shape of the pH gradient [35]. The use of commercially prepared IPG 
DryStrip, introduced by Bjellqvist et al. [36] and Gorg et al. [37] eliminates these 
variations. The pH gradient is immobilized by covalent incorporating Immobiline® 
acrylamide buffers into the acrylamide matrix during polymerization. Since Immobiline 
consists of discrete, relatively simple molecules, they can be manufactured very 
reproducibly pure, eliminating batch effect as demonstrated by interlaboratory 
comparison [35][38]. Further, pI resolution to 0.01 pH unit can be achieved [36]. The 
acryl amide matrix with the Immobiline, acryl amide buffers is cast onto a baking sheet, 
polymerized, washed and dried. The backing gives the strips size stability and simplify 
handling. The dried strips can be rehydrated in various buffers and additives that would 
inhibit polymerization if included at the time of casting [35]. 
 
Second dimension. 
 
Prior to the second dimension (Sodium Dodecyl SulphatePolyAcrylamide Gel 
Electrophoresis-SDS-PAGE), the IPG strips are equilibrated twice with gentle shaking 
in a solution containing urea and glycerol in order to diminish electroendosmotic effects 
[37] which are held responsible for reduced protein transfer from the first to the second 
dimension. DTT, a reducing agent, is added to the first and iodoacetamide (IAA) to the 
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second equilibration step [39]. IAA is added to the equilibration buffer in order to 
remove excess DTT (responsible for the "point streaking" in silver stained patterns) 
[40]. After equilibration the strips are applied to vertical SDS gels in order to perform 
electrophoresis and to separate proteins according to their molecular weight. 
Polypeptides separated can be visualized by Coomassie Blue, silver staining, 
fluorescence or autoradiography, or by "specific" stains such as glycoprotein staining or 
immunochemical detection methods [31]. Whereas the "general" protein stains are 
carried out in the electrophoresis gel directly, immunochemical detection methods are 
usually performed after electrophoretic transfer ("blotting") of the separated 
polypeptides from the electrophoresis gel onto an immobilizing membrane [41][42]. 
Today, among the variety of methods used for protein detection after gel 
electrophoresis, fluorescent methods offer an interesting compromise, especially for 
detection linearity and for compatibility with mass spectrometry[43]. Stained spots 
excised from the electrophoresis gel can be identified by mass spectrometry. 
 
Mass Spectrometry, nanoLC-ESI-MS/MS 
 
In traditional protein chemistry, proteins were identified by de novo sequencing using 
automated Edman degradation. Today, this technique is replaced by mass spectrometry, 
which is becoming one of the most powerful techniques in protein chemistry. The 
reason for this is the increase in sensitivity (until 1000fold) and the speed of analysis. 
Today, the Nanoscale liquid chromatography coupled to tandem mass spectrometry 
(nano LC–MS/MS) has become an essential tool in the ﬁeld of proteomics, due to your 
enormous analytical advantages when dealing with sample-limited situations. Tandem 
mass spectrometry has been used as a microscale de novo sequencing tool for peptides 
because collision-induced dissociation (CID) followed by product ion scanning provides 
systematic fragment information of amino acid sequences. Further improvement in 
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peptide sequencing sensitivity was accomplished by the development of 
nanoelectrospray combined with a peptide sequence tag approach for protein 
identification in databases. Because even one peptide is sufficient to identify a unique 
protein, this approach is more powerful for protein identification in proteome-scale 
experiments than the peptide fingerprinting approach where several peptide masses 
from one protein are used for identification[44]. For proteomic analysis, proteins are 
normally ﬁrst cleaved into peptides by enzymatic digestion (i.e., usually by trypsin) and 
subsequently, separated by reversed phase (RP) Nano LC before data-dependent 
MS/MS analysis [52]. The typical microcolumns for nanoLC are prepared using RP 
materials with a  3-10μm diameter packed into fused silica capillaries with a 12-100μm 
diameter. In ESI-MS, a spray needle is used as a restrictor for packed particles to 
prepare a fritless column, to minimize the post-column dead volume [44]. Generally, 
smaller colums at a lower flowrate combined with real nanoelectrospray conditions give 
higher sensitivity. For peptides, in combination with C18 stationary phases, acidic 
conditions are usually used: Trifluoroacetic acid (TFA) is one of the most popular 
reagents because of higher peak capacity with smaller peak width while Acetonitrile or 
Methanol have been used as an organic solvent in off-line infusion. Finally, because of 
the low flowrate, and the small size ranges of proteomic samples (<100μl), trap columns 
are useful to reduce the injection time. Spots of interest are excised from the gel and 
treated with tripsin, an enzyme that cleaves C-terminal to arginine (R) and lysine (K). 
The mixture of protein fragments (peptides) obtained after digestion is purified and 
subjected to mass analysis. 
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AIM 
The aim of the present study was to carry out a non-hypothesis based proteomic 
investigation, in order to identify potential specific disease-related biomarkers in acute 
psychotic bipolar disorder (PBD). We performed a comparative proteomic analysis by 
using two-dimensional electrophoresis (2DE) coupled to mass spectrometry (MS) of 
lymphocyte protein samples from patients affected by PBD,  Major Depression (MDE) 
and Healthy Control (HC) to identify a potential proteins able to discriminate between 
the three classes of patients and to suggest associated dysfunctional molecular pathways 
in the acute psychotic features. 
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METHODS 
Patients 
Forty-one subjects (26 patients and 15 healthy) participated in the study. The patients 
were recruited from the Day Hospital and Inpatient Service of the U.O. Psichiatria II, 
AOUP. All patients were 
given an in-house case report form (CRF) for socio-demographic assessment; record of 
current pharmacological treatment at the time of taking blood and basic medical 
information. The26 patients were divided into two classes: 15 patients (4 males and 11 
females; mean age 40.5 years ±9.31), were enrolled in the PBD class. The mean age at 
the onset of illness was 28.1 years(±11.32) and mean illness duration was 12.50 years 
(±9.6).Eleven patients (2 male and 9 females; mean age 36.5 ± 9.36),were recruited in 
the MDE class. The mean age at the onset of illness was 27 years (±11.2) and the mean 
illness duration was9.53 (±7.14). All patients in the PBD class were admitted to hospital 
in the acute phase, after a PBD. At the time of blood collection they had been on 
medication (a combination of mood stabilizers, benzodiazepines and antiPBDs) for 2 
days (±1), with the exception of one patient who was totally unmedicated. All patients 
belonging to this class showed acute full-blown psychotic episodes in the context of 
BD. Seven patients had a diagnosis of the most recent manic episode, 5 had a diagnosis 
of the most recent depressive episode, and 3 had a diagnosis of most recent mixed 
episode. None of these patients had a family history of psychosis; however, 9 patients 
out of 15 had a family history of mood disorders. All patients included in the MDE class 
had a diagnosis of major depressive episode, 6 patients had a second Axis I diagnosis of 
panic disorder, 5 patients had a family history of mood disorders, but none of these 
patients had a family history of psychosis. In terms of medication, 6 patients were in 
mono-therapy with SSRIs, 1 patient was in combined treatment of SSRIs and 
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benzodiazepines (BDZ), 1 patient in combination of bupropion and gabapentin and 3 
patients in combination of SSRIs and mood stabilizers. The healthy subjects(10 female 
and 5 male; mean age around 38.9 ± 12.1), were 
recruited from among the hospital staff. The inclusion criteria were age range between 
20 and 50 years and fasting at the time of blood collection. All the subjects were 
admitted to the study after screening for the absence of metabolic diseases (obesity 
,metabolic syndrome, diabetes, hormonal disorders), current fever or infectious disease, 
current substance abuse or dependence, pregnancy or refusal to sign informed consent 
to the study. 
 
Clinical features 
The patients were assessed from the socio-demographic point of view by using the 
Structured Clinical Interview for DSM-IV Patient version (SCID-I-P), according to 
DSM-IV in which are established the criteria to determine the presence or the absence 
of DSM IV Axis I  disorders. Patients were also assessed by means of PANSS [45], 
YMRS [46], HAM-A and HAM-D-17 [47][48] questionnaires. 
 
Lymphocyte preparation and protein extraction 
 
From all subjects, a peripheral venous blood sample of 25 ml was obtained and placed 
in EDTA tubes. The blood samples were immediately processed to obtain lymphocyte 
fraction as previously described.25 Briefly, blood was centrifuged for 15 min at300g to 
obtain a platelet-rich plasma (PRP) and a pellet containing red cells, platelets, 
granulocytes, lymphocytes (P1). Platelets were precipitated from PRP by centrifugation 
at 3000g for 10 min to obtain platelet-free plasma (PFP). P1 was diluted 1 : 1 with 
Emagel(Behring AG, Marburg, Germany) and centrifuged for 30 min at550g at room 
temperature over a density gradient of Lymphoprep (Nycomed, Oslo, Norway). A 
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lymphocyte ring was thus obtained at the interface between the plasma and the 
Lymphoprep. Lymphocytes were harvested and washed in phosphate buffered saline 
(PBS) at 300g for 15 min. The resulting pellet  was diluted with 1 ml PBS, stratified in 
7 ml of PFP and centrifuged at 600g for 15 min. Lymphocytes were washed twice in 
PFP to obtain a sample that was completely separated from platelets. The pellets of cells 
were resuspended in rehydration solution (7 M Urea, 2 M thiourea, 4% CHAPS, 60 mM 
DTT, 0.002% bromophenol blue) in which the Protease Inhibitor Cocktail (5 μl ml-1) 
(Sigma-Aldrich; MO, USA) and Halt Phosphatase Inhibitor Cocktail  (10 μl ml-1) 
(Thermo Fisher Scientific; IL, USA) were added, and incubated for 30 min at room 
temperature. After incubation, the samples were centrifuged for 5 min at 16 000g to 
remove undissolved material. Protein concentrations were measured using a RC–DC 
protein assay from Bio-Rad using bovine serum albumin as the standard. All samples 
were stored at -80 °C until analysis. 
 
2DE, staining and image analysis 
The 2DE analysis was performed in triplicate.  200 µg of proteins, for each sample, 
were filled up to 450 µl in rehydration solution (supplemented with 1.2% (v/v)IPG-
buffer, pH 3–10 NL). Isoelectrofocusing (IEF) was carried out by using 18 cm 
Immobiline Dry-Strips (GE Health Care, WI,USA) with a non-linear, pH 3–10 gradient 
(IPG strips). IEF was performed on an EttanIPGphor II apparatus (GE Health Care)at 
16 °C and the proteins were focused for up to 70000 V h. The second dimension (SDS-
PAGE) was carried out by transferring  the proteins into 12.5% polyacrylamide gel, 
running at16 mA per gel and 10°C for about 16 h, using the PROTEAN-IIMulti Cell 
system (Bio-Rad, CA, USA) [49]. At the end of the 2DE, the gels were stained with 
Ruthenium II tris (bathophenanthrolinedisulfonate) tetrasodium salt (SunaTech Inc.; 
Suzhou, P. R. China)(RuBP) [50]. The images were acquired upon fluorescence 
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imaging using ‘‘Image Quant LAS4010’’(GE-Healthcare). The analysis of images was 
performed using Progenesis Same Spot (v4.1, Nonlinear Dynamics; Newcastle Upon 
Tyne, UK)[49][50]. 
 
NanoLC-ESI-MS/MS Analysis and protein identification. 
 Spots of interest were cut out from gel reference and the nanoLCESI-MS/MS analysis 
by LTQ-OrbitrapVelos was performed. Peak lists were generated from raworbitrap data 
using the embedded software from the instrument vendor (extract_MSN.exe). The 
monoisotopic masses of the selected precursor ions were corrected using an in-house 
written Perl script [51]. The peak list files were searched against the UniProtKB/Swiss-
Prot database (Release-2011_08 of 21-Sep-2011)using Mascot (Matrix Sciences, 
London, UK). Human taxonomy(20 323 sequences) was specified for database 
searching. The parention tolerance was set to 10 ppm. Variable amino acid 
modifications were oxidized methionine and fixed amino acid modifications were 
carbamidomethylcysteins. Trypsin was selected as the enzyme, with one potential 
missed cleavage, and the normal cleavage mode was used. The mascot search was 
validated using Scaffold 4.0 (Proteome Software, Portland, OR). Only proteins 
matching with two different peptides with a minimum probability score of 95% were 
considered identified. 
 
Western Blot analysis 
All samples were processed using WB analysis to validate different protein expressions 
found by 2DE analysis. 25 µg of proteins were resolved by 12% SDS-PAGE gels and 
transferred onto nitrocellulose membranes (0.2 μm) using a voltage of 25 V for 7 min 
(Trans-Blots Turbot Transfer System; Bio-Rad). After electrophoresis, we progress the 
standardization as follows: the membranes were fixed in 7% acetic acid (v/v) and 10% 
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methanol(v/v) for 15 min, subsequently rinsed in water, and stained with 1 mM RuBP 
in 1% phosphoric acid and 30% ethanol for15 min. After this the membranes were 
rinsed in water prior to the acquisition of the total proteins by ‘‘ImageQuant 
LAS4010’’(GE HealthCare). After acquisition, the membranes were blocked and then 
incubated with appropriately diluted primary antibodies. The primary antibodies used 
were anti-LASP1 (rabbit polyclonal, 1 : 1000 dilution; Novus Biological, CO, USA), 
anti-SCAD (rabbit polyclonal, 1 : 300 dilution; Novus Biological, CO, USA), anti-
STIP1anti-Hop (D6E3) (rabbit monoclonal, 1 : 1000 dilution, Cell Signaling 
Technology Inc., MA,USA) and anti-TPD52L2 (goat polyclonal, 0.2 mg ml_1 dilution; 
Thermo Fisher Scientific, IL, USA). HRP-conjugated goat anti-rabbit(1 : 20 000 
dilution; Stressgen, NY, USA) and HRP-conjugated donkey anti-goat (1 : 5000 dilution; 
Santa Cruz Biotechnology Inc., CA, USA) were used as secondary antibodies. The 
chemiluminescent images were acquired by LAS4010 (GE Health Care). For the 
comparison of protein expression levels among the three classes(PBD, MDE and HC), 
the antigen specific bands and the total proteins were quantified using the Image Quant-
TL (GE HealthCare). In order to normalize the volume of proteins of interest, the ratio 
of optical density of the antigen-specific bands with those of total proteins was 
calculated. The results were express as a ratio of optical density. 
 
Statistical Analysis 
 In 2DE analysis, the comparison between PBD, MDE and HC was performed. The 
significance of the differences of normalized volume for each spot was calculated by the 
software Progenesis Same Spot including the analysis of variance (ANOVA) test. The 
protein spots with a Z1.5-fold spot quantity change and p<0.05 were cut out from the 
gel and identified using (nanoLC-ESI-MS/MS) analysis. Data obtained from the WB 
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analysis were subjected to statistical analysis with unpaired Student’s t-test making a 
comparison of protein expression levels between the three classes. 
 
Signalling pathway analysis 
Functional pathway and network analyses were generated using the IPA software v7.1. 
Proteins that met the expression ratio with a cut-off of ≥1.5, and a p value cut-off of 
<0.05 for differential expression, and those that were associated with a canonical 
pathway in the Ingenuity Pathways Knowledge Base, were considered for the analysis. 
Swiss-Prot accession numbers were inserted into the software along with the 
corresponding comparison ratios between the groups. The network proteins associated 
with biological functions and/or diseases in the Ingenuity Pathways Knowledge Base 
were considered for the analysis. These networks were scored for the degree of 
relevance, with values>3 having a 99.9% confidence level of not being generated by 
random chance alone. The genetic networks that were created describe the functional 
relationships between gene products based on known associations in the literature. 
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RESULTS 
Clinical assessment 
The demographic characteristics of all the subjects enrolled in the study are shown in 
Table 1. 
       Table 1. Demographic details of enrolled subjects   
 
In Table 2 are reported the clinical assessment data for each class. The two classes differ 
significantly in Positive and Negative Symptoms Scale (PANSS) total score( p < 0.001), 
positive symptoms subscale ( p < 0.001), negative symptoms subscale (p = 0.005), and 
psychopathology subscale ( p <0.001). No statistical difference was observed for 
Hamilton Depression Rating Scale (HAM-D-17) and Hamilton Anxiety Rating Scale 
(HAM-A) mean scores, while Young Mania Rating Scale(YMRS) mean total score was 
statistically different ( p = 0.001)between the two classes. 
 
 
 
 
                      Table 2. Clinical assessment of patients 
 
 PBD 
 (n=15) 
MDE 
(n=11) 
HC 
 (n=15) 
Gender (male/female) 4/11 2/9 10/5 
Age (years) mean (±SD) 40.5 (±9.31) 36.5 (±9.36) 38.9 (±12.1) 
Age at onset mean (±SD) 28.1 (±11.32) 27 (±11.2) - 
Illness duration mean (±SD) 12.5 (±9.6) 9.53 (±7.14) - 
Smokers 6/15 3/11 2/15 
 PBD MDE p-value 
PANSS 83,7 (±25,4) 39,9 (± 5,8) <0.001 
PANSS_P 26,3 (± 5,8) 8,4 (± 8,3) <0.001 
PANSS_N 12,6 (± 8,1) 7,1 (± 4,6) =0.005 
PANSS_G 44,8 (± 15,6) 25,5 (± 4,5) <0.001 
HAM-D 15,2 (± 16,7) 10,9 (± 5,5) NS 
HAM-A 12,2 (± 6,3) 11,6 (± 3,5) NS 
YMRS 23,3 (± 13,1) 1,9 (± 3,2) =0.001 
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Proteomic analysis 
A comparative proteomic analysis was performed on lymphocyte samples from patients 
with PBD, major depressive episode (MDE)and healthy control (HC) subjects by using 
2DE coupled to nano-liquid chromatography electro spray ionization tandem 
MS(nanoLC-ESI-MS/MS). Fig. 1 shows a representative gel image of lymphocytes 
from PBD patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Representative 2DE gel map of PBD lymphocyte protein extracts. A total of 200 mg of 
proteins was separated by 2DE using an 18 cm pH 3–10 NL strip and 12.5% SDS-PAGE. 
Proteins were detected by RuBP staining. The maps were analyzed by Progenesis Same Spot 
(Nonlinear Dynamics) software. Spots numbers indicate all the proteins identified by MS/MS 
and refer to the number reported in Table 3. 
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By computational 2DE gel image comparison, 36 protein spots, which collapsed into 25 
different proteins, were found to be differentially expressed. These spots exhibited  
≥1.5-fold change of the mean value of normalized spot intensities in the lymphocyte 
preparations of PBD and MDE patients with respect to HC subjects. The list of 
identified proteins is given in Table 3: here, MS (matched peptides ,coverage and best 
ion score) and 2DE (ratio, p-values) are also reported. Fig. 2 shows the histogram of the 
normalized optical density volumes (mean SEM) of the proteins found indifferent 
quantities in the comparison among the three classes. 
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Table 3. MS/MS data of protein spots differentially expressed among PBD, MDE and HC samples
# 
No  
ID 
ProteinName 
Gene 
Name 
pI MW Match. 
pep. 
Cov. 
 (%) 
Best 
Ion 
Score 
BDP vs Ctr MDE vs Ctr BDP vs MDE 
a b a b F.V p-value F.V p-value F.V p-value 
565 P02787 Serotransferrin TF 5,8 6,8 75 77 15 23 82,5 4,4 >0.0001 4,4 >0.0001 1,00 ns 
567 P02787 Serotransferrin TF 5,9 6,8 75 77 20 28 96,3 5,9 >0.0001 6,5 >0.0001 0,90 ns 
656 P18206 Vinculin VCL 5,3 5,5 66 124 2 2 62,2 3,0 >0.0001 3,2 >0.0001 0,96 ns 
783 P02768 Serumalbumin ALB 5,6 5,9 62 69 42 63 86,5 4,4 0.001 8,4 >0.0001 0,53 0.027 
827 P31948 Stress-induced-phosphoprotein 1 STIP1 5,8 6,4 61 63 3 5 65,5 2,2 0.0007 1,4 ns 1,55 0.037 
872 P02768 Serumalbumin ALB 5,4 5,9 59 69 17 25 71,1 2,5 >0.0001 3,3 >0.0001 0,77 0.019 
880 P02768 Serumalbumin ALB 5,7 5,9 59 69 6 11 81 3,2 >0.0001 4,3 >0.0001 0,74 ns 
905 P10809 60 kDa heat shock protein, mitochondrial HSPD1 5,1 5,7 57 61 8 18 57,8 2,2 >0.0001 2,9 >0.0001 0,79 ns 
913 P02675 Fibrinogen beta chain FGB 5,8 8,5 57 56 6 14 90,9 1,8 >0.0001 1,7 0.0084 1,06 ns 
920 P02675 Fibrinogen beta chain FGB 5,9 8,5 56 56 16 32 88,8 2,6 >0.0001 2,4 >0.0001 1,09 ns 
923 P02675 Fibrinogen beta chain FGB 6,0 8,5 56 56 19 41 102,4 2,2 >0.0001 2,1 >0.0001 1,07 ns 
951 P08670 Vimentin VIM 5,1 5,1 54 54 2 6 30,2 1,5 0.009 2,0 0.004 0,75 ns 
984 P07437 Tubulin beta chain TUBB 4,8 4,8 53 50 3 9 57,3 1,9 0.0002 2,2 >0.0001 0,88 ns 
1007 P07437 Tubulin beta chain TUBB 4,9 4,8 51 50 2 7 50,2 1,5 >0.0001 1,8 >0.0001 0,86 ns 
1012 P02768 Serumalbumin ALB 5,5 5,9 51 69 23 33 113,7 2,3 >0.0001 2,9 >0.0001 0,81 0.011 
1089 P01871 Ig mu chain C region IGHM 5,7 6,4 48 49 2 6 70,2 2,3 >0.0001 2,9 >0.0001 0,77 ns 
1241 P60709 Actin, cytoplasmic 1  or 2 ACTB 5,7 5,3 43 42 6 24 100,8 0,5 >0.0001 0,3 >0.0001 1,43 ns 
1261 P60709 Actin, cytoplasmic 1 or 2 ACTB 5,3 5,3 42 42 4 14 43,5 0,6 >0.0001 0,6 >0.0001 0,99 ns 
1334 P00738 Haptoglobin HP 5,2 6,1 41 45 11 26 85,1 2,0 >0.0001 2,1 >0.0001 0,97 ns 
1340 P16219 
Short-chain specific acyl-CoA dehydrogenase, 
mitochondrial 
ACADS 5,8 8,1 41 44 2 6 75 2,8 >0.0001 1,4 ns 1,95 ns 
1446 P14618 Pyruvate kinase isozymes M1/M2 PKM 5,9 8,0 39 58 2 4 42,2 3,2 >0.0001 2,2 0.002 1,47 ns 
1481 Q13347 Eukaryotic translation initiation factor 3 subunit I EIF3I 5,3 5,4 38 37 3 10 44,2 0,4 >0.0001 0,3 >0.0001 1,24 ns 
1586 P11177 
Pyruvatedehydrogenase E1 component subunit 
beta, mitochondrial 
PDHB 5,2 6,2 36 39 4 15 70,8 0,4 >0.0001 0,4 >0.0001 1,19 ns 
1606 P0C0L4 Complement C4-A C4A 6,0 6,7 36 192 3 2 46,3 2,5 >0.0001 2,6 >0.0001 0,99 ns 
1650 P27482 Calmodulin-likeprotein 3 CALML3 5,7 4,3 35 17 2 19 40 3,7 >0.0001 2,5 >0.0001 1,46 ns 
1714 Q14847 LIM and SH3 domain protein 1 LASP1 5,5 6,6 34 30 3 15 51,3 3,0 >0.0001 1,7 0.048 1,84 ns 
1742 O00299 Chlorideintracellularchannelprotein 1 CLIC1 5,1 5,1 33 27 6 31 89,2 0,4 >0.0001 0,4 >0.0001 1,10 ns 
1823 O43399 Tumorprotein D54 TPD52L2 5,2 5,3 32 22 2 12 70,6 2,6 0.0014 1,2 ns 2,25 ns 
1843 P15259 Phosphoglyceratemutase 2 PGAM2 5,9 9,0 32 29 2 5 29,1 3,3 >0.0001 2,9 >0.0001 1,14 ns 
1904 P63104 14-3-3 protein zeta/delta YWHAZ 4,7 4,7 31 28 9 41 107,7 0,3 >0.0001 0,3 >0.0001 1,12 ns 
1980 P60174 Triosephosphateisomerase TPI1 6,9 5,7 30 31 3 15 91,1 2,4 >0.0001 2,7 >0.0001 0,89 ns 
2056 P02647 Apolipoprotein A-I APOA1 5,6 5,7 29 31 3 15 29,2 3,7 >0.0001 2,9 >0.0001 1,28 ns 
2076 P02647 Apolipoprotein A-I APOA1 5,1 5,7 29 31 16 43 80 1,9 >0.0001 1,8 0.001 1,05 ns 
2641 P00738 Haptoglobin HP 5,5 6,1 24 45 3 4 82,8 6,6 >0.0001 4,2 >0.0001 1,59 0.033 
2659 P00738 Haptoglobin HP 5,7 6,1 24 45 5 12 82,2 6,0 >0.0001 3,6 >0.0001 1,69 ns 
3082 P02766 Transthyretin TTR 5,3 5,5 20 16 2 18 68 3,5 >0.0001 3,9 >0.0001 0,90 ns 
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Figure 2. Comparison of differentially expressed proteins. Histograms of the normalized optical 
density volumes (mean ± SEM) of the 25 protein spots found in significantly different quantities 
from the comparison between PBD and HC (*p<0.05, **p<0.01, ***p<0.001) and MDE and 
HC (#p<0.05, ##p< 0.01, ###p<0.001). Significant differences from HC is based on unpaired 
Student t test. 
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Validation of proteins in PBD, MDE and HC lymphocyte preparations by WB 
analysis 
Immunoblot analysis was performed to confirm the ability of short-chain specific acyl-
CoA dehydrogenase mitochondrial (SCAD), LIM and SH3 domain protein1 (LASP1), 
tumor protein D54 (TPD52L2) and stress-induced protein 1 (STIP1) to discriminate 
PBD from MDE as suggested by 2DE observations(Fig. 3A). After statistical analysis, 
all these proteins resulted in being differentially expressed in a significant manner in 
PBD when compared to HC samples, with increased values of 2.2-,14-, 16- and 2.7-fold 
for SCAD, LASP1, TPD52L2 and STIP1respectively. Moreover, the efficacy of LASP1 
and SCAD to discriminate PBD from MDE was confirmed. Representative western 
blots are shown in Fig. 3B. 
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Figure 3.WB validation of selected differentially expressed proteins. SCAD, LASP1, TPD52L2 and STIP1 differential expressions by immunoblot analysis. 
Conventional SDS gels were run with lymphocytes protein extracts from all subjects using 12% resolving capacity. Twenty-five micrograms of total proteins were 
loaded into each lane, proteins were transferred onto nitrocellulose membranes and incubated with specific antibodies against the target proteins. Panel A: 
representative 2DE enlarged images of validated proteins. Panel B: the western blot is representative of one sample appertaining to PBD, HC and MDE class, 
respectively. The bar graph shows the mean ± SEM of the optical density values. The staining by RuBP was used as a protein loading control. Statistically 
significant differences were determined by the unpaired Student t test and the p values are indicated. (PBD vs. HC: *p<0.05,**p<0.01; MDE vs. HC: #p<0.05; 
PBD vs. MDE: $p<0.05). 
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Network construction for biological processes 
The assignment of biological processes and the subsequent construction of networks 
were done using the IPA software v7.1(Ingenuity®System Inc., Redwood City, CA, 
USA. www.ingenuity.com). Twenty-five proteins that showed significant change in the 
expression between psychiatric disorders (PBD and MDE)and HC lymphocytes samples 
were included in the analysis. Each identified protein was converted to its gene and 
mapped onto its corresponding gene object in the IPA knowledge base .A network with 
a score value of 38 was generated and the director indirect relationships exhibited by the 
proteins among each other within the network are shown in Fig. 4. 
The network shows 35 proteins that work together in neurological diseases 
,psychological disorders and the amino acid metabolism network and 15 of 25 proteins 
were included in the network. We utilized IPA to retrieve the known functions of each 
protein. The major categories of network-associated functions included cellular 
movement, cell-to-cell signaling and interactions inflammatory response and molecular 
transport. All in all, 16 of our proteins were found to be involved in neurological disease 
( p-value 2.9 x 10
-10
 to 3.1 x 10
-2
), 14 in inflammatory disease (p-value 7.7 x 10
-8
 to 2.6 
x 10
-2
) and 16 in psychological disorders ( p-value 2.9 x 10
-10
 to 1.1 x 10
-2
). The 
collocation of our proteins in the context of the canonical pathways involved in acute 
phase response signaling, LXR-RXR activation, glycolysis, 14-3-3mediated signaling, 
NRF2-mediated oxidative stress-response and IL-8 signaling (Fig. 4) is noteworthy. 
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Figure 4. IPA network analysis of differentially expressed proteins. Twenty-five proteins that 
showed significant change in expression between psychiatric disorders (PBD and MDE) and 
HC lymphocytes samples were included in the analysis. The network shows 35 proteins that 
work together for Neurological diseases, Psychological disorders and Amino acid metabolism 
network. Solid lines correspond to direct protein-to-protein interactions/regulations, dashed 
lines correspond to indirect interactions/regulations. Proteins involved in acute phase response 
signaling, LXR-RXR activation, glycolisis, 14-3-3 mediated signaling, NRF2-mediated oxidative 
stress-response and IL-8 signaling canonical pathways are indicated. 
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DISCUSSION 
The proteomic approach leads to the suggestion of molecular distinguishing markers for 
many diseases, which are lacking for psychiatric disorders, despite the large incidence 
of psychiatric disorders such as BD, schizophrenia and major depression. The most 
difficult tasks remain the multifactorial characteristics of psychiatric disorders, the 
overlapping of symptoms among all, and drug abuse. Nevertheless, information derived 
from a protein fingerprint could provide new insights into the molecular interaction 
involved in the disease progression and then improve then characterization of the 
disease. 
In this study, we performed a comparative proteomic analysis of lymphocyte protein 
samples from patients affected by PBD, MDE and HC. This approach should identify 
potential proteins able to discriminate between the two classes of patients and to suggest 
associated dysfunctional molecular pathways in the acute psychotic features. The 
patients enrolled for the study underwent accurate characterization, and the sample 
collections followed standard procedures to improve the reliability of the results. 
Lymphocytes were chosen since different studies demonstrated that alterations in 
peripheral blood cell neurotransmitter signaling pathways reflected the changes 
observed in CNS, together with much evidence of altered immune functions in these 
diseases[21][22]. By using high performance 2DE coupled with nanoLC-ESI-MS/MS 
analysis we identified 25 proteins in PBD lymphocytes that were differentially 
expressed with respect to HC. Twenty-one of these proteins were also differentially 
expressed in MDE lymphocytes when compared with controls converging in a common 
signature for these disorders. However, of the remaining up regulated proteins (LASP1, 
STIP1, SCAD and TPD52L2) only SCAD andLASP1 were confirmed as discriminatory 
proteins between PBD and MDE after WB validation. The acyl CoA dehydrogenases 
(ACAD) are a family of enzymes that catalyze the alpha and beta dehydrogenation of 
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the acyl-CoAesters, transferring electrons to electron transferring flavoprotein(ETF). In 
humans, very long, medium and short chain ACAD(VLAD, MCAD, and SCAD, 
respectively) catalyze the first step in the beta-oxidation cycle with substrate optima of 
16, 8 and 4carbon chains, respectively. SCAD acts within mitochondria, the energy-
producing centers within cells, and it is essential for fatty acid oxidation, which is the 
multistep process that metabolizes fats and converts them into energy. Our results 
suggested a significant increase of SCAD in PBD lymphocyte preparations with respect 
to MDE and HC. An alteration of expression of this protein has been also recently 
reported by Kazuno and co-workers[25] in whole cell lysate derived from 
lymphoblastoid cells of monozygotic twins discordant for BD, even if the observed 
decrease of protein expression in the patient was found to be not significant. Therefore, 
we can hypothesize that the increase of SCAD in PBD lymphocytes may be seen as a 
compensatory effect to maintain a constant velocity of acetyl CoA production in the 
cell. As far as LASP1 is concerned, it is important to note that the up regulation 
observed in the patients was particularly high in the PBD. LASP1 is a multi domain 
protein that may recruit signaling molecules to the actin based cytoskeleton and an 
association with susceptibility to schizophrenia has been suggested[53]In this context 
the observed differential expression of cytoskeletal proteins ,i.e. tubulin beta chain, 
actin, vinculin, vimentin could also be explained. On the other hand, as regards 
cytoskeletal proteins appertain to serum but we found their significant differential 
expression in PBD and MDE lymphocyte preparations when compared with HC. At the 
same time, as suggested by Herbert et al.[23]in PBMC and by Politi and co-
workers[54]in endothelial cells, different circulating hormonal or inflammatory factors 
or serum analytes may interact in different manners with these cells to determine 
detrimental effects or sensibilization phenomena, which might be responsible for 
internalization of the molecules. Nevertheless, these proteins were unable to 
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discriminate PBD and MDE inflammatory profiles showing very similar values of 
increase and decrease with respect to HC. It is noteworthy that the IL-8specific pathway 
seems different in PBD in light of the direct interaction with LASP1 that in turn 
modulates cytoskeletal proteins. Our results agree with those reported by Herberth et 
al.[23] that showed the differential expression of cytoskeletal and stress response 
proteins in peripheral blood mononuclear cells (PBMC)together with serum-associated 
proteins linked to inflammatory response, as signatures of BD. To examine if the 25 
identified proteins found were related to each other and constituted a global molecular 
network and pathway, we applied IPA analysis to our data. The results showed that the 
differentially expressed proteins work together for neurological diseases, psychological 
disorders and amino acid metabolism network, and the principal network-associated 
functions were cellular movement, cell to cell signaling and interactions, and 
inflammatory response. Worthy of attention was the collocation of our proteins in the 
context of the canonical pathways that focused on the involvement of acute phase 
response signaling ,LXR-RXR activation, glycolysis, 14-3-3 mediated signaling, NRF2-
mediated oxidative stress-response and IL-8 signaling. In our network the inflammatory 
response is associated with proteins such as ApoA1, HP, TTR,TF, and FGB, which 
correlate directly or indirectly with pro inflammatory cytokine and different protein 
kinases. Intriguingly, all the above named proteins appertain to serum but we found 
their significant differential expression in PBD and MDE lymphocyte preparations 
when compared with HC. At the same time, as suggested by Herbert et al.[23] in PBMC 
and by Politi and co-workers[54] in endothelial cells, different circulating hormonal or 
inflammatory factors or serum analytes may interact in different manners with these 
cells to determine detrimental effects or sensibilization phenomena, which might be 
responsible for internalization of the molecules. Nevertheless, these proteins were 
unable to discriminate PBD and MDE inflammatory profiles showing very similar 
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values of increase and decrease with respect to HC. It is noteworthy that the IL-
8specific pathway seems different in PBD in light of the direct interaction with LASP1 
that in turn modulates cytoskeletal  proteins. If this way might be preferential in PBD 
with respect to other ones ,the relation between STIP1 and the peptide hormones LH 
and FSH, whose increase has been observed and correlated with side effects such as 
depression, triggering mania and aggression in treated BD subjects, needs to be 
investigated. 
 
 
CONCLUSIONS 
The novelty of this work is the analysis of patients with psychosis in the context of BD 
and in particular all patients belonging to this class showed an acute full-blown 
psychotic episode (manic or depressive episode) in the context of BD. Most of the 
proteome studies reported in the literature have been carried out on samples from 
patients with schizophrenia, while mood disorders samples have only been used in a 
validation context for schizophrenia. Our choice has limited the number of patients 
included in the study and surely a larger number of patient samples, ideally collectedin 
different hospital settings, would increase the confidence of our findings. Nevertheless 
our results confirm the reliability of lymphocytes as a peripheral model to study 
psychiatric disorders, and to prove the difficulty in defining specific biomarkers due to 
the significant overlap of disease clinical profiles. However ,we believe that the increase 
of SCAD found in PBD lymphocytes might provide new insights into the molecular 
pathways involved in acute full-blown PBD symptoms. 
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